595 related articles for article (PubMed ID: 18702647)
21. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Bader el-Din NG; Abd el-Meguid M; Tabll AA; Anany MA; Esmat G; Zayed N; Helmy A; el-Zayady AR; Barakat A; el-Awady MK
J Gastroenterol Hepatol; 2011 Jan; 26(1):55-62. PubMed ID: 21175794
[TBL] [Abstract][Full Text] [Related]
22. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a.
Nasta P; Gatti F; Puoti M; Cologni G; Bergamaschi V; Borghi F; Matti A; Ricci A; Carosi G
AIDS; 2008 Apr; 22(7):857-61. PubMed ID: 18427204
[TBL] [Abstract][Full Text] [Related]
23. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
24. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection.
Simó R; Lecube A; Genescà J; Esteban JI; Hernández C
Diabetes Care; 2006 Nov; 29(11):2462-6. PubMed ID: 17065685
[TBL] [Abstract][Full Text] [Related]
25. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4.
Khattab MA; Eslam M; Shatat M; Abd-Aalhalim H; Mousa YI; Samir F; Aly H; Shaker O; Shaker Y
J Gastrointestin Liver Dis; 2012 Mar; 21(1):59-65. PubMed ID: 22457861
[TBL] [Abstract][Full Text] [Related]
26. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
27. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection.
Dore GJ; Torriani FJ; Rodriguez-Torres M; Bräu N; Sulkowski M; Lamoglia RS; Tural C; Clumeck N; Nelson MR; Mendes-Correa MC; Godofsky EW; Dieterich DT; Yetzer E; Lissen E; Cooper DA
AIDS; 2007 Jul; 21(12):1555-9. PubMed ID: 17630550
[TBL] [Abstract][Full Text] [Related]
28. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
29. Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study.
Morisco F; Stroffolini T; Medda E; Amoruso DC; Almasio PL; Villa E; Zuin M; Paris B; Stanzione M; Caporaso N;
J Viral Hepat; 2010 Jun; 17(6):427-34. PubMed ID: 19780939
[TBL] [Abstract][Full Text] [Related]
30. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
31. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
32. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
Saad Y; Ahmed A; Saleh DA; Doss W
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
[TBL] [Abstract][Full Text] [Related]
33. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Jensen DM; Morgan TR; Marcellin P; Pockros PJ; Reddy KR; Hadziyannis SJ; Ferenci P; Ackrill AM; Willems B
Hepatology; 2006 May; 43(5):954-60. PubMed ID: 16628671
[TBL] [Abstract][Full Text] [Related]
34. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis.
Amarapurkar DN; Patel ND; Kirpalani AL
Trop Gastroenterol; 2007; 28(1):16-8. PubMed ID: 17896604
[TBL] [Abstract][Full Text] [Related]
35. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
36. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
37. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
Giannini EG; Basso M; Savarino V; Picciotto A
Aliment Pharmacol Ther; 2010 Feb; 31(4):502-8. PubMed ID: 19925499
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
39. PEG-IFN and ribavirin re-treatment of HCV-1b cirrhosis non responder to conventional combination therapy.
Morisco F; Amoruso D; Stroffolini T; Caporaso N
Dig Liver Dis; 2008 May; 40(5):391-2. PubMed ID: 18291731
[No Abstract] [Full Text] [Related]
40. DOES INSULIN RESISTANCE IMPAIR THE VIROLOGICAL RESPONSE TO PEGINTERFERON/RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS?
Laurito MP; Silva GF; Cheinquer H; Sharma R; Verna E; Parise ER
Arq Gastroenterol; 2018; 55(2):179-183. PubMed ID: 30043870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]